Shares of Inogen Inc (NASDAQ:INGN) have been assigned an average recommendation of “Hold” from the ten brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $195.80.
Several research firms have weighed in on INGN. TheStreet cut Inogen from a “b-” rating to a “c+” rating in a report on Thursday, January 3rd. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research report on Thursday, February 14th. BidaskClub lowered Inogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 15th. Needham & Company LLC reissued a “strong-buy” rating and issued a $191.00 target price (down previously from $280.00) on shares of Inogen in a research report on Wednesday, February 27th. Finally, Piper Jaffray Companies decreased their target price on Inogen from $290.00 to $185.00 and set an “overweight” rating for the company in a research report on Wednesday, February 27th.
In related news, Director Raymond Huggenberger sold 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $136.81, for a total transaction of $1,162,885.00. Following the completion of the transaction, the director now owns 11,297 shares of the company’s stock, valued at approximately $1,545,542.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 5.29% of the stock is owned by company insiders.
NASDAQ INGN traded down $1.03 during trading on Thursday, reaching $90.22. The company’s stock had a trading volume of 47,688 shares, compared to its average volume of 496,161. The firm has a market capitalization of $2.00 billion, a P/E ratio of 39.14, a P/E/G ratio of 3.22 and a beta of 1.49. Inogen has a one year low of $88.71 and a one year high of $287.79.
Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 26th. The medical technology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.19. The business had revenue of $86.50 million for the quarter, compared to analyst estimates of $82.06 million. Inogen had a return on equity of 18.60% and a net margin of 14.48%. The company’s quarterly revenue was up 35.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) EPS. On average, sell-side analysts expect that Inogen will post 1.91 EPS for the current fiscal year.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also: Short Selling
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.